Cassava Sciences fined $40m over misleading Alzheimer’s drug trial results
In a sensational revelation, Cassava Sciences, Inc., a biotechnology company that has been the center of attention for its experimental Alzheimer’s drug, is now embroiled in controversy. The U.S. Securities and Exchange Commission (SEC) has charged the company and two former executives for allegedly misleading investors with false claims about their clinical trials. This development […]